A Study effect of Aprepitant(Medicine) on cough in patients of lung cancer
Phase 2
- Conditions
- Health Condition 1: null- Lung cancer patients having chronic cough more than 2 weeks, on cough suppressant as per treating physician choice
- Registration Number
- CTRI/2017/05/008691
- Lead Sponsor
- Tata Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 128
Inclusion Criteria
1.Male or female patients aged 18 years or older
2.Lung cancer patients with advanced stage
3.Having chronic cough more than 2 weeks, and on regular cough suppressant.
4.ECOG performance score 0-2
5.Able to give informed consent
6.Willing to follow the trial related activities
Exclusion Criteria
1.ECOG performance score >= 3
2.Patient receiving aprepitant .
3.Patient using pimozide for psychiatric illness, as aprepitant increases level of pimozide by decreaing metabolism, causes life threatening QT prolongation.
4.As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease)
5.Pregnancy or breast feeding.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method